Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non-Hodgkin's lymphoma

    Oncotarget, 2015.

    Cited by: 0|Bibtex|Views1|Links
    WOS
    Keywords:
    PI3K pathwayXC-302non-hodgkin lymphomapharmacokineticssafety and efficacy

    Abstract:

    To determine the safety of Puquitinib Mesylate (XC-302), an oral inhibitor of phosphatidylinositol 3-kinase, in treating relapsed or refractory non-Hodgkin's lymphoma (NHL).Between October 2013 and July 2015, 21 patients from Sun Yat-sen University Cancer Center were treated twice daily on each day of a 28-day cycle (median number of cycl...More

    Code:

    Data:

    Your rating :
    0

     

    Tags
    Comments